Peer-influenced content. Sources you trust. No registration required. This is HCN.

ASCO Educational BookOvercoming KRAS-Mutant Lung Cancer

This comprehensive review highlights the history of discovering RAS and the decades of studies targeting KRAS-driven lung cancer, to the present applications. Although KRAS inhibitors have 36%–45% objective response rates with a median duration of response of 10 months, many tumors do not respond, and a variety of mechanisms of resistance have been observed, including new KRAS alterations, activation of alternate RTK pathway proteins, bypass pathways, and transcriptional remodeling. The authors conclude with a discussion of ongoing clinical trials aimed at overcoming resistance to KRAS inhibitors.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form